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Intimate Partner Violence (IPV) is widespread and more prevalent in the HIV positive 
population (1). However there is little published work concerning IPV in this population in 
the UK (2). Dhairyawan et al (3) found a 52% lifetime prevalence of IPV in HIV positive 
women in a London clinic, with 14% reporting IPV in the last year. Health Care Workers have 
been identified as professionals to whom patients might choose to disclose IPV (4). 
 
Screening for IPV is recommended in selected health care settings, and at our hospital there 
is a new post for an Independent Domestic and Sexual Violence Advisor (IDSVA). We 
established screening in an Out Patient HIV clinic and compared those screened with those 
not, and summarised the characteristics of those reporting current or previous IPV.  
 
Multidisciplinary staff were trained to ask the following standardised question: “Have you 
ever been emotionally or physically hurt by your partner, ex-partner or family member?” 
Those who answered positively were assessed for current or past IPV by asking, “Are you still 
in contact with this person and are they still causing you and your family issues?” Screening 
took place while the patient was alone in a private place. Patients were referred to 
Safeguarding services if necessary and to the IDSVA. If referral to the IDVSA was declined or 
there was no current risk, leaflets and contact information was given.  
 
We report on the demographics of 348-screened patients.  Data were collected over 5 
months and recorded on a standardised sheet  and linked to the HIV database by hospital 
number and then anonomysed. Groups were compared using chi-squared tests or Fisher’s 
Exact test for categorical variables, and using Mann-Whitney U tests for continuous variables 
as they were not Normally distributed. No formal adjustment for multiple testing was made. 
 
10% (348/3383) of the current clinic population was screened. Those screened had similar 
demographics and HIV markers to those not screened. Almost a third of participants  
(103/348,30%), had ever experienced IPV, and were more likely to be female (p=0.01) with a 
trend towards heterosexual risk group (p=0.085) and a detectable viral load (p=0.088). 
68/348(20%) had experienced IPV in the past and 35/348(10%) of those screened were 
experiencing current IPV or were given contact information for future self referral. 
14/348(4%) agreed to be referred to the IVDSA. Ten were women and 7/14 had Black 
ethnicity. Other variables were similar to the whole population except seven of those 
referred had detectable viraemia (50% vs. 15%). Although numbers are small perhaps this 
may suggest a relationship between adherence and access to medication, which could be 
further explored. Among the 103 who screened positive as a group there was also a trend 
towards detectable viraemia (p=0.088) 
 
There was evidence of differences also when comparing men whom screened positive for 
IPV according to risk group. Of the 224 men who were screened, 54 (24.1%) reported 
previous or current IPV. When stratifying by risk for HIV acquisition, 38/119 (24.2%) MSM, 
6/44 (13.6%) of heterosexual men, 9/16 (56.3%) of IDU and 1/8 (12.5%) of other risk men 
reported current/previous IPV (p=0.0326). 
 
There was no evidence of a difference by age (see Table 1). Furthermore, the median (range) 
age of men who were screened for DV was 48 (18-75) years and the median age of women 
was 44 (16-77) years. When included in the multivariable logistic regression model, the 
estimate for men vs women was materially unchanged (OR=0.34; 95% CI 0.15-0.75; 
p=0.0080). 
 
Compared to other specialities in our hospital undertaking screening, IPV was more 
commonly reported, for example 5.7% in GUM services (5). This may be because those with 
HIV are a more vulnerable group. Screening was often performed by a person with whom 
the patient had a long-standing relationship, which may encourage disclosure.Those whom 
experienced past IPV were offered referral to the Psychology service. Future work could look 
at age/gender-matched controls across different hospital departments. This pilot suggests 
the pathway is robust and a variety of staff could be successfully trained.  
 
There are limitations to this study, which could be explored in future work. Although the 
relationship of the perpetrator to the victim was known it was not recorded on the 
screening proforma. Neither was the nature of the IPV, which was wide ranging including 
physical, verbal and sexual abuse, blackmail and financial control, threats to disclose HIV 
status and with-hold  Antiviral medication (personal communication S. Madge). We did not 
record education or employment demographics.This screening tool was  useful as it 
included” a family member” as a possible perpetrator, and this could contribute towards the 
relatively high detection rate of IPV. 
 
HIV positive patients experience a high lifetime risk for IPV and warrant further investigation 
as a high-risk group. A Clinic setting appears to be an appropriate venue for screening and 
referral by a variety of Health Care workers using this tool and pathway. Staff reported that 
although screening was sometimes time consuming they felt it improved their satisfaction 
with the consultation. Patients could also be asked about their experience and opinion. 
More patients should be screened with more detailed data recorded to establish common 
factors for those at highest risk. The possible relationship between viral load and current IPV 
merits further exploration. Detectable viraemia might be a trigger for discussion about IPV in 
the HIV clinic. 
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Table 1- Characteristics, according to whether individual was 

















N 348 103 245 3035   
Male gender 224 
(64.4%) 





Age (years)       
Median (range) 47 (16, 77) 46 (25, 77) 47 (16, 77) 46 (17, 86) 0.73 0.79 
Ethnicity     0.0227 0.37 
White 172 
(49.4%) 





Black African 97 (27.9%) 25 (24.3%) 72 (29.4%) 725 (23.9%)   
Other 79 (22.7%) 28 (48.5%) 51 (20.8%) 576 (19.0%)   
Risk     0.0017 0.085 
MSM 157 
(45.1%) 












Other 37 (10.6%) 15 (14.6%) 22 (9.0%) 234 (7.7%)   












Ever had AIDS 
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Total length of 











Table 2- Characteristics, according to whether whether individual 
had ever experienced DV, further stratified by gender 
  Women Men 
  Positive screen Negative screen Positive screen Negative screen 
N 49 75 54 170 
Age (years)         
Median (range) 44 (25-77) 44 (16-77) 48 (31-67) 48 (18-75) 
Ethnicity         
White 11 (22.5%) 11 (14.7%) 39 (72.2%) 111 (65.3) 
Black African 29 (59.2%) 49 (65.3%) 4 (7.4%) 36 (21.2) 
Other 9 (18.4%) 15 (20.0%) 11 (20.4%) 23 (13.5) 
Risk         
MSM - - 38 (70.4%) 119 (70.0) 
Heterosexual 44 (89.8) 66 (88.0) 6 (11.1) 38 (22.4) 
Other 5 (10.2) 9 (12.0) 10 (18.5) 13 (7.7) 
Time since diagnosis (years) 
Median (range) 
11.5 (1.3-25.2) 10.5 (0.2-23.9) 10.9 (0.2-27.7) 11.8 (0.0-29.5) 
Ever had AIDS diagnosis 13 (26.5) 21 (28.0) 12 (22.2) 44 (25.8) 
CD4 nadir (cells/mm3) 200 (0-452) 187 (7-783) 198 (150-1604) 189 (1-707) 
CD4 current (cells/mm3) 534 (114-1055) 560 (123-1369) 637 (150-1604) 566 (9-1501) 
VL<50 copies/ml 34 (75.6) 63 (90.0) 46 (85.2) 148 (87.1) 
Total length of ART (years) 9.6 (0.2-22.3) 9.5 (0.6-23.9) 9.4 (0.2-20.9) 10.2 (0.4-23.9) 
  
